Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › FDA Approves Expanded Use of Agilent CDx for Keytruda in Lung Cancer

FDA Approves Expanded Use of Agilent CDx for Keytruda in Lung Cancer

Apr 17, 2019
|
staff reporter

NEW YORK (360Dx) – Agilent Technologies announced on Tuesday that the US Food and Drug Administration has expanded its approval of the firm's Dako PD-L1 IHC 22C3 pharmDx assay as a companion diagnostic test for Merck's anti-PD1 immunotherapy pembrolizumab (Keytruda) for non-small cell lung cancer (NSCLC).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Revokes Emergency Use Authorization for Autobio Diagnostics SARS-CoV-2 Serology Test

  2. What's Holding Up Home Testing for SARS-CoV-2?

    Premium

  3. BioMérieux, Beijing Wantai Coronavirus Antibody Tests Get FDA Emergency Use Authorization

  4. Helix Gets FDA Emergency Use Authorization for NGS-Based COVID-19 Test

  5. Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.